Portal de Periódicos da CAPES

Fluid balance control in critically ill patients: results from as-treated analyses of POINCARE-2 randomized trial

2023; BioMed Central; Volume: 27; Issue: 1 Linguagem: Inglês

10.1186/s13054-023-04701-5

1466-609X

Adil Mansouri, Marie Buzzi, Sébastien Gibot, Claire Charpentier, Francis Schneider, Guillaume Louis, Hervé Outin, Alexandra Monnier, Jean‐Pierre Quenot, Julio Badié, Laurent Argaud, Cédric Bruel, Marc Soudant, Nelly Agrinier, Camille Alleyrat, Jean‐Marc Virion, Pierre‐Édouard Bollaert, Jérémie Lemarié, Ionel Alb, P. Welfringer, Rostane Gaci, M. Bemer, Eric Delaveuve, Elsa Tahon, Pascal Andreu, Marie Labruyère, Jean-Baptiste Roudaut, Bruno Maire, Laurent Ziegler, Vincent Castelain, François Philippart, Marc Tran, Martin Cour, Marie Simon, Neven Stevic, Jann Hayon, Matthieu Jamme, Fernando Berdaguer, Hakim Slimani,

Cardiac, Anesthesia and Surgical Outcomes

Intention-to-treat analyses of POINCARE-2 trial led to inconclusive results regarding the effect of a conservative fluid balance strategy on mortality in critically ill patients. The present as-treated analysis aimed to assess the effectiveness of actual exposure to POINCARE-2 strategy on 60-day mortality in critically ill patients.POINCARE‑2 was a stepped wedge randomized controlled trial. Eligible patients were ≥ 18 years old, under mechanical ventilation and had an expected length of stay in ICU > 24 h. POINCARE-2 strategy consisted of daily weighing over 14 days, and subsequent restriction of fluid intake, administration of diuretics, and/or ultrafiltration. We computed a score of exposure to the strategy based on deviations from the strategy algorithm. We considered patients with a score ≥ 75 as exposed to the strategy. We used logistic regression adjusted for confounders (ALR) or for an instrumental variable (IVLR). We handled missing data using multiple imputations.A total of 1361 patients were included. Overall, 24.8% of patients in the control group and 69.4% of patients in the strategy group had a score of exposure ≥ 75. Exposure to the POINCARE-2 strategy was not associated with 60-day all-cause mortality (ALR: OR 1.2, 95% CI 0.85-1.55; IVLR: OR 1.0, 95% CI 0.76-1.33).Actual exposure to POINCARE-2 conservative strategy was not associated with reduced mortality in critically ill patients. Trial registration POINCARE-2 trial is registered at ClinicalTrials.gov (NCT02765009). Registered 29 April 2016.